The US National Institutes of Health Awards DNDi with a 3-Year Grant Dedicated to the Development of a Low-Cost Treatment for Visceral Leishmaniasis

[ Geneva, Switzerland – November 5, 2007 ]
The National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), has granted Drugs for Neglected Diseases initiative (DNDi) USD 2.3 million to be disbursed over 3 years for research and development that focuses on developing a low-cost formulation of amphotericin B to treat visceral leishmaniasis.

Advinus Therapeutics and DNDi Join Forces on Drug Discovery and Development for Visceral Leishmanias (Kala Azar)

[ Bangalore and Geneva October  11, 2007 ]
Advinus Therapeutics (P) Ltd. and Drugs for Neglected Diseases initiative (DNDi), a not-for-profit R&D organization based in Geneva, Switzerland, announced today that they have formed a collaboration for discovery and development of novel therapies for visceral leishmaniasis (kala azar), a fatal infectious disease of developing countries including India.

New, Once-a-Day Fixed-Dose Combination Against Malaria Now Available

[ Paris – March 1st, 2007 ]
Sanofi-aventis and the non-profit Drugs for Neglected Diseases initiative (DNDi) announced today that ASAQ, the new fixed-dose combination of artesunate (AS) and amodiaquine (AQ), will soon be available throughout sub-Saharan Africa. ASAQ is the first drug developed by the FACT (Fixed-dose, Artemisinin-based Combination Therapy) partners, managed by DNDi in partnership with sanofi-aventis.
[Français]